Vosoritide is a treatment developed to treat achondroplasia. Achondroplasia is a skeletal dysplasia (a condition affecting children’s bones and joints meaning they do not grow in the typical way) and is also referred to as dwarfism. Vosoritide has been shown to increase the growth velocity of children with achondroplasia. This video summarizes a recent plain language summary discussing reports from two clinical studies investigating vosoritide as a potential treatment for achondroplasia.
The content of this video is based on the authors’ recent article, ‘Vosoritide treatment accelerates bone growth in children with achondroplasia’, published in Future Rare Diseases. Read the article at https://www.futuremedicine.com/doi/10.2217/frd-2021-0009.
Vosoritide treatment accelerates bone growth in children with achondroplasia
Ravi Savarirayan, Melita Irving, Julie Hoover-Fong et al.
Future Rare Diseases 1(3) (2021) DOI: 10.2217/frd-2021-0009